ABIVAX Soci?t? Anonyme - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ABVX Nasdaq 2836 www.abivax.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ABIVAX Soci?t? Anonyme

Abivax Announces Results of its June 6, 2025 Annual General Meeting - Jun 11th, 2025 2:00 pm
Abivax Presents First Quarter 2025 Financial Results - Jun 2nd, 2025 2:00 pm
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis - Apr 29th, 2025 2:05 pm
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones - Apr 22nd, 2025 2:05 pm
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors - Apr 22nd, 2025 2:00 pm
Abivax publishes financial reports with the French and U.S. securities regulatory agencies - Mar 26th, 2025 3:05 pm
Abivax Announces Full Year 2024 Financial Results - Mar 24th, 2025 1:30 am
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 - Feb 21st, 2025 12:30 am
Abivax Publishes 2025 Financial Calendar - Jan 28th, 2025 12:30 am
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress - Jan 23rd, 2025 2:05 pm
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment - Jan 9th, 2025 9:35 am
Abivax Announces a Change to the Composition of its Board of Directors - Dec 23rd, 2024 2:05 pm
Why ABIVAX Société Anonyme (ABVX) is the Best All-Time Low Stock to Buy Right Now? - Dec 4th, 2024 2:42 pm
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq - Nov 19th, 2024 2:30 pm
Abivax presents third quarter 2024 key financial information - Nov 14th, 2024 2:01 pm
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax - Nov 13th, 2024 2:01 pm
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation - Oct 7th, 2024 2:01 pm
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease - Oct 3rd, 2024 2:01 pm
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance - Oct 3rd, 2024 12:31 am
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 - Sep 26th, 2024 12:30 am